The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer

por Hadji, Peyman, Ziller, May, Maurer, Tobias, Autenrieth, Michael, Muth, Mathias, Ruebel, Amelie, May, Christoph, Birkholz, Katrin, Diebel, Erhardt, Gleissner, Jochen, Rothe, Peter, Gschwend, Juergen E.
Publicado 2012

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemes...

por Hadji, Peyman, Stoetzer, Oliver, Decker, Thomas, Kurbacher, Christian M., Marmé, Frederik, Schneeweiss, Andreas, Mundhenke, Christoph, Distelrath, Andrea, Fasching, Peter A., Lux, Michael P., Lüftner, Diana, Janni, Wolfgang, Muth, Mathias, Kreuzeder, Julia, Quiering, Claudia, Grischke, Eva-Marie, Tesch, Hans
Publicado 2018

Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or meta...

por Tesch, Hans, Stoetzer, Oliver, Decker, Thomas, Kurbacher, Christian M., Marmé, Frederik, Schneeweiss, Andreas, Mundhenke, Christoph, Distelrath, Andrea, Fasching, Peter A., Lux, Michael P., Lüftner, Diana, Hadji, Peyman, Janni, Wolfgang, Muth, Mathias, Kreuzeder, Julia, Quiering, Claudia, Taran, Florin‐Andrei
Publicado 2018

FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

por Fasching, Peter A, Jud, Sebastian M, Hauschild, Maik, Kümmel, Sherko, Schütte, Martin, Warm, Matthias, Hanf, Volker, Grab, Dieter, Krocker, Jutta, Stickeler, Elmar, Kreienberg, Rolf, Müller, Thomas, Kühn, Thorsten, Wolf, Christopher, Kahlert, Steffen, Paepke, Stefan, Berghorn, Michael, Muth, Mathias, Baier, Monika, Wackwitz, Birgit, Schulz-Wendtland, Rüdiger, Beckmann, Matthias W, Lux, Michael P
Publicado 2014